Review examines why children often receive medicines outside official labels
The article argues that off-label use in children can be evidence-based, while important gaps in pediatric research and regulation remain.
Low evidenceReviewSome caution advised
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
The authors discuss United States and European efforts to increase pediatric medicine research and labeling information. They say these programs have not fully closed the evidence gap because pediatric studies may be delayed, incomplete, or postponed until after a medicine reaches the market.
The review separates unsupported off-label use from prescribing supported by research, clinical guidelines, or established clinical experience. Examples are discussed in pediatric cancer care, child psychiatric disorders, and supportive care, but the excerpts do not provide new patient-level results from these areas.
What the review examined
The article reviewed the regulatory and clinical evidence surrounding off-label medicine use in children. It discusses United States programs, European pediatric regulations, and the Italian experience, including efforts intended to support pediatric prescribing. The available excerpts do not state that the authors conducted a systematic literature search, meta-analysis, or new study involving a defined number of patients.
What the evidence shows
The authors conclude that off-label prescribing is common in pediatrics and is not inherently the same as inappropriate prescribing. They report that some off-label uses are supported by scientific evidence, guidelines, or long-standing clinical experience, even when the official label has not been updated. They also conclude that pediatric research and regulatory systems remain incomplete, with delays in required studies, limited enforcement, and ongoing shortages of suitable formulations for some children, including neonates. These are conclusions of a narrative review and synthesis, not results from a new clinical trial.
Who this may apply to
The discussion is broadly relevant to pediatric healthcare and medicine regulation, especially in settings similar to those described in the United States, Europe, and Italy. It does not provide evidence that applies directly to every child, condition, medicine, dose, formulation, or clinical situation. It also should not be read as showing that off-label prescribing is generally appropriate; the article itself says that appropriateness depends on the strength and relevance of the evidence, the clinical context, and safety monitoring.
What this could mean
Children may receive medicines without complete pediatric information in the official product label. The review highlights that regulatory status alone may not fully describe the evidence behind a prescription, while also emphasizing that off-label use can be poorly supported in some situations. Its discussion is relevant to how pediatric medicines are researched, regulated, and evaluated, but it does not establish that any particular off-label medicine is effective or safe for an individual child.
Limitations & evidence assessment
The excerpts provide no detailed methods for how evidence was searched, selected, or judged, and no quantitative synthesis is reported. The article relies partly on studies cited as background or related evidence rather than presenting new patient data. The review also makes broad claims across several conditions and countries, but the available text does not give enough detail to determine how representative the cited evidence is. The excerpts are incomplete, so additional limitations may not be visible.
Why this evidence level: This is a review and discussion article rather than a new clinical study, systematic review, or formal guideline. The excerpts do not describe a systematic search, study selection process, or quantitative synthesis, so the strength of its overall conclusions cannot be independently assessed from the available information.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
// Source
The Italian Journal of Pediatrics/Italian journal of pediatrics · 2026 · DOI: 10.1186/s13052-026-02348-w
Researchers pooled results from seven human studies comparing multiple-staged with single-stage removal and reconstruction of congenital melanocytic nevi, sometimes called congenital moles. Staged surgery was associated with fewer major wound complications and recurrences, as well as slightly shorter and narrower scars, but the studies did not find a clear difference in cosmetic or overall patient satisfaction.
A cluster-randomized human study in 210 adults with recently detected stage 1 hypertension in Uzbekistan compared salt-sensitivity testing followed by assigned medication choices with conventional management. After 12 weeks, more participants in the testing-guided group reached the study's blood pressure target, although the study was small, short, and conducted in only three primary care centers.
This human randomized trial compared repeated use of a study hand-sanitizer formulation with a commercially available 79.7% ethanol sanitizer among 568 employees and cohabiting family members in Japan. The study-formulation group had fewer reported upper respiratory symptoms and illness-related work restrictions during the 72-day winter study, although the findings do not establish how well they apply to other populations or longer periods.
